Valeant Says It's Under Investigation by SEC, Shares Plunge
- Stock adds to earlier declines, falls by 18 percent Monday
- SEC probe said to be separate from Salix investigation
Valeant: Under Investigation by SEC
This article is for subscribers only.
Valeant Pharmaceuticals International Inc. said it is under investigation by the U.S. Securities and Exchange Commission in a previously undisclosed probe.
The drugmaker said in a statement that it received a subpoena from the SEC in the fourth quarter and would have disclosed it in due course in its 10-K filing, which has been delayed. It didn’t provide further details on the probe.